Displaying 1181 - 1200 of 1346
SmithKline Beecham Corp. v. Apotex Corp.
Announced Actions for November 22, 2002
America Online, Inc., and Time Warner Inc.
AOL and Time Warner Inc. settled Commission concerns relating to their proposed merger. The order requires AOL Time Warner to open its cable system to competitor internet service providers. In addition, the company is prohibited from interfering with content passed along the bandwidth contracted for by non- affiliated internet service providers; and prohibited from interfering with the ability of non- affiliated providers of interactive television services to interact with interactive signals that AOL Time Warner agreed to carry.
FTC and DOJ to Hold Roundtable Discussions To Conclude Hearings on Competition and Intellectual Property Law and Policy
Possible Anticompetitive Efforts to Restrict Competition on the Internet
FTC Releases Agenda for Public Workshop on Possible Anticompetitive Efforts to Restrict Competition on the Internet
FTC Files Amicus Brief Opposing Barriers to Internet Casket Sales
Announced Actions for July 24, 2002
FTC to Host Public Workshop to Explore Possible Anticompetitive Efforts to Restrict Competition on the Internet
Muris to Detail E-Commerce Workshop Focused on The Costs And Consequences to Consumers of State Regulations and Business Agreements
FTC/DOJ Hearings to Highlight U.S. Court of Appeals For the Â鶹´«Ã½ Circuit Perspectives on the Intersection Between Antitrust and Intellectual Property Law and Policy
Administrative Law Judge Bars Distributors of Three Tenors Media from Agreeing to "Fix, Raise, or Stabilize" Prices
Biovail Corporation
The Commission charged Biovail Corporation with illegally acquiring an exclusive patent license for Tiazac, a pharmaceutical used to treat high blood pressure and chronic chest pain. The complaint further alleged that Biovail, in an effort to maintain its monopoly, wrongfully listed the acquired license in the U.S. Food and Drug Administration’s “Orange Book†for the purpose of blocking generic competition to its branded Tiazac. The consent order requires Biovail to divest part of its exclusive rights to DOV; prohibits the firm from taking any action that would trigger additional statutory stays on final FDA approval of a generic form of Tiazac; and also prohibits Biovail from wrongfully listing any patents in the Orange Book for a product for which the company already has an New Drug Application from the FDA.
FTC Issues Complaint Against Rambus, Inc.
FTC/DOJ Hearings Continue to Highlight the Intersection of Antitrust and Intellectual Property Law and Policy
FTC/DOJ Hearings to Highlight the Intersection Between Antitrust and Intellectual Property Law and Policy
FTC Protecting Children's Privacy Online
Displaying 1181 - 1200 of 1346